MA, Nakamuta H, Motta A. Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helix. J Biol Chem. 2006 Aug 25;281(34):24193-203. \[[PubMed: 16766525](https://pubmed.ncbi.nlm.nih.gov/16766525)\] 23. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest. 1986 Aug;78(2):355-60. \[[PMC free article: PMC423551](/pmc/articles/PMC423551/)\] \[[PubMed: 3016026](https://pubmed.ncbi.nlm.nih.gov/3016026)\] 24. Carstens JH, Feinblatt JD. Future horizons for calcitonin: a U.S. perspective. Calcif Tissue Int. 1991;49 Suppl 2:S2-6. \[[PubMed: 1933616](https://pubmed.ncbi.nlm.nih.gov/1933616)\] 25. Overgaard K, Agnusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1991 Feb;72(2):344-9. \[[PubMed: 1846873](https://pubmed.ncbi.nlm.nih.gov/1846873)\] 26. Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol. 1985 Apr-Jun;3(2):155-7. \[[PubMed: 2410171](https://pubmed.ncbi.nlm.nih.gov/2410171)\] 27. Latif A, Gastelum AA, Farhan K, Jagadesh S, Mutnuri S. Treatment approach for primary hyperparathyroidism in pregnancy. Proc (Bayl Univ Med Cent). 2020 Oct 28;34(1):191-193. \[[PMC free article: PMC7785157](/pmc/articles/PMC7785157/)\] \[[PubMed: 33456198](https://pubmed.ncbi.nlm.nih.gov/33456198)\] 28. Peña-Rodríguez ZA, Haro-García M, Benito-Navarro JR. Nasal osteoma and inhaled salmon calcitonin: Coincidence or consequence? Acta Otorrinolaringol Esp (Engl Ed). 2017 Nov-Dec;68(6):366-368. \[[PubMed: 28069111](https://pubmed.ncbi.nlm.nih.gov/28069111)\] 29. Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013 Dec;47(12):1675-84. \[[PubMed: 24259626](https://pubmed.ncbi.nlm.nih.gov/24259626)\] 30. Ishii J, Katayama S, Itabashi A, Takahama M, Kawazu S. Salmon calcitonin induces pituitary tumor in rats. Endocrinol Jpn. 1991 Dec;38(6):705-9. \[[PubMed: 1823038](https://pubmed.ncbi.nlm.nih.gov/1823038)\] 31. Sondergaard BC, Catala-Lehnen P, Huebner AK, Bay-Jensen AC, Schinke T, Henriksen K, Schilling S, Haberland M, Nielsen RH, Amling M, Karsdal MA. Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus. Osteoarthritis Cartilage. 2012 Feb;20(2):136-43. \[[PubMed: 22122987](https://pubmed.ncbi.nlm.nih.gov/22122987)\] 32. Wells G, Chernoff J, Gilligan JP, Krause DS. Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporos Int. 2016 Jan;27(1):13-9. \[[PMC free article: PMC4715844](/pmc/articles/PMC4715844/)\] \[[PubMed: 26438308](https://pubmed.ncbi.nlm.nih.gov/26438308)\] 33. Tanaka S, Yoshida A, Kono S, Ito M. Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: An open-label, randomized, parallel-group study. J Orthop Sci. 2017 May;22(3):536-541. \[[PubMed: 28108224](https://pubmed.ncbi.nlm.nih.gov/28108224)\] **Disclosure:** Matthew McLaughlin declares no relevant financial relationships with ineligible companies. **Disclosure:** Ayoola Awosika declares no relevant financial relationships with ineligible companies. **Disclosure:** Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.